ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

Phase 3CompletedNCT01980095

RedHill Biopharma Limited119 enrolled

Overview

The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients.

This is a, randomized, double-blind, placebo-controlled study of RHB-105 in adult subjects complaining of epigastric discomfort that have been screened and found to be positive for H. pylori infection via 13C Urea Breath Test (UBT) and either fecal antigen test or CLO test. Eligible subjects will be randomized in a ratio of 1:2 between placebo arm (n=30) and the active arm (RHB-105) (n=60). Subjects will receive study drug for 14 consecutive days. Eradication of H. pylori infection will be determined based on 13C UBT conducted between 28 to 56 days after completion of study drug therapy. Subjects will be unblinded upon 13C UBT analysis. This will provide timely active therapy to all subjects enrolled in this study. Subjects in the placebo arm will be entitled to receive standard-of-care as prescribed by the treating physician following un-blinding. Eradication failures (13C UBT-positive) in the active study drug arm will undergo upper endoscopy with sampling for culture and sensitivity testing (to rifabutin, amoxicillin, clarithromycin, and metronidazole). Culture and sensitivity directed therapy as prescribed by the treating physician will be offered to these subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

119

Conditions

Dyspepsia Helicobacter Pylori Infection

Interventions

RHB-105DRUG

The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of: * Rifabutin 150 mg * Amoxicillin 3000 mg * Omeprazole 120 mg Subjects will take study drug every 8 hours with food for 14 consecutive days.

PlaceboDRUG

Subjects will take 4 placebo capsules every 8 hours with food for 14 days.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Be ≥18 years of age and ≤ 65 years 2. Have symptoms consistent with dyspepsia of at least two weeks duration (defined as recurrent pain or discomfort centered in the upper abdomen, often with a relation to meals) 3. Be positive for H. pylori by 13C Urea Breath Test (UBT) and also by fecal antigen test 4. Be informed of the nature of the study and provide written informed consent before any study specific procedures are performed (or have a legally authorized representative sign consent) Exclusion Criteria: 1. Have alarm symptoms/signs (including unexplained anemia \[iron deficiency), melena / hematemesis, anorexia, dysphagia, jaundice, weight loss) 2. Have taken antibiotics in the 4 weeks prior to screening 3. Have taken bismuth containing medications such as peptobismol in the 4 weeks prior to screening 4. Have a history of any previous esophageal or gastric surgery, except for simple closure of perforated ulcer 5. Have a history of gastric outlet obstruction 6. Have a history of hypersecretory state such as Zollinger-Ellison Syndrome 7. Have a history of gastric cancer 8. Have the presence of active gastric and duodenal ulcers or presence of 3 or more active ulcers

Locations (12)

Anaheim Clinical Trials, LLC

Anaheim, California, United States

Anaheim Clinical Trials

Anaheim, California, United States

Catalina Research Institute

Chino, California, United States

Outcomes

Primary Outcomes

The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing

Modified intent-to-treat (mITT) population analyzed included all participants whok received at least 1 dose of study drug and underwent a 13C Urea Breath Test (UBT) at Visit 4. Participants with negative test results were to be considered treatment successes. Patients who tested positive for H. pylori infection, and those with indeterminate, not assessable, or missing results were to be considered treatment failures. The statistical hypothesis that the active treatment is superior to 70% was to be tested against the alternative hypothesis that the active treatment is statistically indistinguishable or less than 70% effective using a one-sample Z-test.

Time frame: 28-56 days after completion of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.